

Supplemental Figures




Figure S1. Sanger sequencing for miR27A. Highlighted is rs895819, with the top panel showing a homozygous wildtype, middle heterozygote and bottom homozygous variant.

Table S1. Severe fluoropyridine related adverse events during total treatment period.

	Genotype	Grade ≥ 3 Toxicity ¹ during total treatment period N, (%)	OR (95% CI) (adjusted)	P-value
Total Treatment Period	Wildtype	63 (35)	1.0 (reference)	0.2792
	<i>DPYD</i> Carriers ²	12 (27)	0.67 (0.31 to 1.36)	
Cycles 1 & 2	Wildtype	46 (26)	1.00 (reference)	0.1536
	<i>DPYD</i> Carriers ²	7 (16)	0.53 (0.20 to 1.21)	

¹Grade ≥ 3 by Common Terminology Criteria for Adverse Events version 5.0; ²*DPYD* variants include c.2846A>T, c.1905+1G>A, c.1679T>G and c.1236G>A.